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Caﬀeineisthemostwidelyconsumedstimulatingsubstanceintheworld.Itisfoundincoﬀee,tea,softdrinks,chocolate,andmany
medications.Caﬀeineisaxanthinewithvariouseﬀectsandmechanismsofactioninvasculartissue.Inendothelialcells,itincreases
intracellular calcium stimulating the production of nitric oxide through the expression of the endothelial nitric oxide synthase
enzyme. Nitric oxide is diﬀused to the vascular smooth muscle cell to produce vasodilation. In vascular smooth muscle cells its
eﬀect is predominantly a competitive inhibition of phosphodiesterase, producing an accumulation of cAMP and vasodilation.
In addition, it blocks the adenosine receptors present in the vascular tissue to produce vasoconstriction. In this paper the main
mechanisms of action of caﬀeine on the vascular tissue are described, in which it is shown that caﬀeine has some cardiovascular
properties and eﬀects which could be considered beneﬁcial.
1.Introduction
Coﬀee is one of the most frequently consumed beverages in
the world. It represents a culture and an economy. It has
been produced in Colombia since the nineteenth century
and is the main export to more than 36 countries; in 2008
it represented close to 12.4% of the harvest of mild Arabica
type coﬀee and 12.2% of worldwide coﬀee exports. There
areapproximately590coﬀeegrowingmunicipalities,513,000
coﬀee growers, 640,000 direct employees, and more than a
million indirect employees, which means approximately 2
million people dependent on coﬀee cultivation [1]
Over 2,000 substances have been isolated from coﬀee.
The major component of coﬀee is carbohydrates, which
make up 38–42% of the toasted coﬀee bean, followed by
lipids and amino acids with about 20 and 10%, respectively.
Melanoidins make up 23% of the weight and are what give
the beans their brown color. They also contain minerals,
aliphatic and chlorogenic acids, trigonellines, and volatile
aromas. Of the alkaloids, the most studied and recognized
one is caﬀeine, which makes up 1.3 to 2.4% of the bean’s
weight [2] followed by other purinic alkaloids such as theo-
bromine and theophylline and pyridine such as trigonelline.
Coﬀee consumption is generally associated with a large
number of diseases and health alterations. However, the
majority of epidemiological studies regarding this relation-
ship have not yielded a clear conclusion, mainly due to the
lack of concrete and continuous information regarding the
frequency of consumption, the exact composition of the
beverage, and factors associated with an unhealthy lifestyle
(cigarette smoking, alcohol, and sedentarism). These aspects
incombinationcouldleadtodiseasesorhealthproblems[3].
Manyepidemiologicstudieshavestudiedtherelationship
between coﬀee consumption and the risk of heart disease.
An analysis [4] of the coﬀee-mortality relationship states
that there is no direct relationship between coﬀee con-
sumption and an increase in mortality; on the contrary,
the authors describe a slightly Inverse relationship between
the consumption of coﬀee and their beneﬁts related to the
inﬂammatory process, endothelial function, and the risk of
developingtype2diabetes.AccordingtoYukawaetal.[5]the
regular consumption of coﬀee reduced susceptibility to low-
density lipoprotein oxidation, a pathway which develops in
atherosclerotic plaques, thus favoring endothelial function.
In another vein, it has been shown that some coﬀee com-
ponents,especiallyphenolics(chlorogenic acid, ferulic acid),2 International Journal of Vascular Medicine
have a great antioxidant capacity [6], and the consumption
of coﬀee is associated with a small reduction in mortality
in women with hepatic disease and/or cirrhosis and shows a
protective eﬀect on the liver in hepatic cancer [7]. Addition-
ally,caﬀeineincreasestheproductionofurinewithwaterand
electrolyte secretion patterns very similar to those seen with
the thiazides [8]. The underlying mechanisms may depend
on various factors such as dose, chronic exposure, genetic
and enzymatic factors, among others. In animal studies
with caﬀeine exposure, an increase in glomerular ﬁltration
and kidney blood ﬂow, especially in the renal medulla, is
seen. In a study of the intrarenal mechanisms responsible
for the natriuretic eﬀect of caﬀeine, the renal secretion
of sodium increased, and the glomerular ﬁltration rate
remained the same, suggesting that diminished fractional
sodium reabsorption, both in the proximal and distal tubule
of the nephron, contributes to the natriuretic eﬀect of
caﬀeine [8]
Caﬀeine is the psychoactive substance most widely
consumed in the world, it is found not only in coﬀee but also
in tea, carbonated beverages or soft drinks, chocolate, and a
wide variety of medications, including appetite suppressants,
diuretics, analgesics, and decongestants; the majority of
which are sold over the counter and do not have a regulatory
control [9, 10]. If you combine the consumption of coﬀee,
tea, chocolate, and soft drinks, the general population
consumes a considerable amount of caﬀeine per day. Adults
overtheageof25haveanestimatedconsumptionofapproxi-
mately2.4mg/kg/day,whilechildrenundertheageof12have
an estimated consumption of approximately 0.7mg/kg/day.
In addition, it has been conﬁrmed that theobromine and
theophylline are alkaloids also found naturally in green tea,
black coﬀee, and cacao [11] however, the direct eﬀect of
these substances on physiological responses to the ingestion
of foods and beverages containing these types of alkaloids,
and the role of each, is not clear.
2. MetabolicPathway of Caffeineand
Its Metabolites
Caﬀeine is metabolized into more than 25 metabolites in
humans, mainly Paraxanthine, Theobromine, and Theo-
phylline [12]
Caﬀeine metabolism yields paraxanthine as a ﬁnal prod-
uct, which represents 72 to 80% of caﬀeine metabolism.
There are ﬁve main metabolic pathways which contribute
to caﬀeine metabolism in adults [13, 14]. The ﬁrst three
consist of demethylization of N-3 to form Paraxanthine,
N-1 to form Theophylline (vasodilator, increased cerebral
and muscular blood ﬂow), and N-7 to form Theophylline
(vascular, bronchiole, muscular, and respiratory relaxant).
ThehepaticcytochromeP-450(CYP)isoenzymemetabolizes
most of the caﬀeine (95%) by three demethylizations which
o na v e r a g eg i v ea ni nv i v om e t a b o l i s mp e r c e n t a g eo f8 5 %
paraxanthine, 10% theobromine, and 5% theophylline [15].
The fourth pathway results in the formation of uracil
metabolites, and the ﬁfth consists of renal elimination of
the remaining percentage of caﬀeine that was not able to be
degraded in the process.
The large interindividual diﬀerences observed in plas-
matic concentration of caﬀeine following the administration
of an equal dose are mainly due to variations in metabolism.
These variations depend on four factors: genetic polymor-
phisms, metabolic induction and inhibition of cytochrome
P-450, individual (weight, sex), and the presence of hepatic
diseases [14]
Caﬀeine is absorbed rapidly and completely from the
intestinal tract, making it 100% bioavailable. The time
in which maximum plasmatic concentration is obtained
(Tmax) is 30–45 minutes [11, 14, 16, 17] fasting and is
delayed with food ingestion; it has an average metabolic half
life in humans of 2.5 to 4.5 hours [18]
3. Vascular Effects of Caffeine
Numerous studies have been carried out to determine
the eﬀect of caﬀeine on the cardiovascular system, with
inconclusive results. Some have found that the consumption
of caﬀeine increases cardiovascular risk [19–21] while others
have described a beneﬁcial or neutral eﬀect on the same
[22–24]. It is evident that the cardiovascular response to
this substance depends on a variety of factors such as the
amount ingested, the time of consumption, the frequency,
degree of absorption, and hepatic metabolism, all aspects
which cause a unique response of each individual to caﬀeine
[25]. In addition to these factors, it is believed that some
substances found in caﬀeinated beverages (theobromine and
theophylline active substances in bronchodilator medica-
tions used in the treatment of respiratory diseases) could
have some eﬀects on the variability of these particular
physiologic responses.
Caﬀeine is a xanthine which acts in the body’s cells
by diﬀerent mechanisms of action and on a wide range
of molecular targets. It intervenes as an antagonist of
the adenosine receptors, inhibitor of phosphodiesterase
enzymes, sensitizer of calcium liberation channels, and
GABA receptor antagonist [26]. Other cardiovascular pro-
cesses are related to the reduction of cytoplasmic Ca2+ in
the vascular smooth muscle cell (VSMC) through cyclic
adenosine monophosphate (cAMP) and the increase of the
same in the endothelial cell, favoring the synthesis of nitric
oxide (NO).
We know that other related substances with a similar
structure to that of the alkaloids present in coﬀee currently
provide an important research tool towards the development
of potential treatments for Alzheimer disease, asthma, can-
cer, diabetes, and Parkinson’s disease [14]. In this paper, the
main mechanisms of action of caﬀeine on the vascular tissue
are described, and we will try to break a series of myths
and paradigms that have negatively inﬂuenced the con-
sumption of coﬀee. These mechanisms are summarized in
Table 1.
4. Mechanisms of Action of Caffeine at
the EndothelialLevel
The endothelium is probably the most extensive tissue in
the human body. It forms an anatomic and functionalInternational Journal of Vascular Medicine 3
Table 1: Summary of the vascular eﬀects of caﬀeine.
Structure Type of eﬀect Eﬀect Reference
Endothelium Direct Activates the ryanodine channels in the ER Zucchi, 1997 [27]
Endo, 1977 [28]
VSMC Direct
Activates the ryanodine channels in the ER Karaki, 1988 [29]
Activates the nonselective channel for cations Guerrero, 1994 [30]
Inhibits the cAMP phosphodiesterase Butcher, 1963 [31]; Ahn, 1988 [32]
Hatano, 1995 [33]
Inhibits the IP3 receptor Missiaen, 1994 [34]
Inhibits MLC kniase Ozaki, 1990 [35]
Increases “noncontractile” Ca2+ Rembold, 1995 [36]
Inhibits voltage-dependent Ca2+ channels Martin, 1989 [37]; Hughes, 1990 [38]
Blocks adenosine receptors Sattin, 1970 [39]
VSMC Indirect
Increases the production of nitric oxide Hatano, 1995 [33]; Umemura, 2006 [40]
Increases the production of renin Tofovic, 1996 [41]; Jackson, 1991 [42]
Stimulates the sympathetic system Corti, 2002 [43]; Robertson, 1978 [44]
VSMC: vascular smooth muscle cell, ER: endoplasmic reticulum, Ca2+: calcium, and MLC: myosin light chain.
barrier covering the arterial walls which is highly selective
and permeable through a continuous, uninterrupted, and
soft surface. It synthesizes and releases a broad spectrum
of vasoactive substances, intervening in the regulation of
VSMC tone through an interaction between vasoconstrictor
(renin, angiotensin, ET-1, etc.) and vasodilator substances
(NO, PgI2, endothelium-derived hyperpolarizing factor,
bradykinin, etc.) [45, 46].
Caﬀeine acts directly on the endothelial cell, stimulating
the production of NO [40]. This eﬀect was evaluated
by blocking the NO pathway with NG-nitro-L-arginine,
oxyhemoglobin, and methylene blue [47]. NO is synthesized
bynitricoxidesynthase(eNOS)fromL-arginineandoxygen.
In order for it to be produced, calmodulin must be bound to
the enzyme, and it only binds in the presence of Ca2+,w h i c h
it obtains from the cytoplasmic content [48].
In the endothelial endoplasmic reticulum, the ryanodine
receptor activity is stimulated by caﬀeine, concentrations
of Ca2+, and adenine nucleotides. Caﬀeine stimulates the
release of Ca2+ from the reticulum, increasing its con-
centration in the cytoplasm (iCa2+), forming a complex
with calmodulin which favors the activation of eNOS. This
mechanism is compatible with the general characteristics
of the calcium-induced calcium release (CICR) [27, 29, 49],
in which a minimal quantity of Ca2+ is required in the
cytoplasm: not enough to activate the eNOS but enough
to stimulate the release of more Ca2+ from the reticulum,
increasing the iCa2+.I ts e e m st h a tc a ﬀeine lowers the
threshold for the activation of CICR, which means that the
m e c h a n i s mi sa c t i v a t e dw i t hp r a c t i c a l l ya tr e s tC a 2+levels
[28].InVSMC,theentrancemechanismsofCa2+ responsible
for a sustained cellular activation are normally mediated
both by voltage-operated Ca2+ channels as well as speciﬁc
receptor [50].
To summarize, the eﬀect of caﬀeine on the vascular
endothelium is a greater expression of NO [21], which has
an autocrine eﬀect, acting on the same endothelial cell to
increase Ca2+, potentiating the response, and coming out
of the endothelial cell to diﬀuse rapidly to the VSMC in a
paracrine fashion [51].
Some authors argue that caﬀeine produces greater
vasodilation by acting on the endothelium than on the
VSMC [33]. However, in in vitro studies carried out by
our group, using rabbit arteries[52] and human internal
mammary arteries, we observed that caﬀeine induces a
potent arterial vasodilator eﬀect in the presence or absence
of preserved endothelial function (Figure 1).
5. Caffeine Mechanisms of Action on
Smooth Muscle Cells
Caﬀeine may exert vascular mechanisms of action through
its direct or indirect eﬀect on the VSMC.
5.1. Direct Eﬀects. Caﬀeine, by acting on the VSMC, gen-
erates a minimal initial contraction and then a signiﬁcant
vasodilatoreﬀect.Therearevariousmechanismsthatexplain
these eﬀects.
5.1.1. Caﬀeine and the Ryanodine Channels. The direct
action of caﬀeine on the VSMC occurs initially through the
ryanodine channels of the sarcoplasmic reticulum, stimulat-
ing the CICR mechanism, which generates an increase in
iCa2+ and a slight transitory contraction [22]. This response
is independent of the amount of extracellular Ca2+ and the
presence of Ca2+ channel blockers [53].
As the intrareticular Ca2+ is used up, the entrance of
extracellular Ca2+ to the cell through the slow (L-type)
channels and the nonselective cation channel in the cell
membranebegins.Caﬀeinedirectlyactivatesthenonselective
cation channel [30] to increase iCa2+. This increase in iCa2+
prolongsthecontractionstartedbytheCICR.Itisinteresting
to note that in the experiments carried out with caﬀeine in
our laboratory [54], in human arteries and animal models,
this contraction was not seen, which leads us to believe that
it is probably a very slight vasoconstrictor eﬀect (Figure 2).4 International Journal of Vascular Medicine
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Figure 1:Relaxationofhumanarteriesinthepresenceofincreasing
doses of caﬀeine. End (+): normal endothelial function; End (−):
endothelial dysfunction. The data are presented as average ± stan-
dard error of the media, which is presented in only one direction
to facilitate the reading of the ﬁgure. It is reproduced with the
authorization of Biom´ edica.
5.1.2. Caﬀeine and cAMP. In vitro experiments carried
out with caﬀeine have demonstrated that in spite of an
increase in the VSMC iCa2+, a vasodilator eﬀect is seen
[55, 56]. Caﬀeine is a nonselective competitive inhibitor of
the phosphodiesterase enzymes [40]. These enzymes have
the capacity to degrade the phosphodiesterase bond in some
compounds such as cAMP and cyclic guanosine monophos-
phate (cGMP). One of the main enzymes inhibited by
caﬀeine is 3 -5  AMP phosphodiesterase [31, 32], whose
function is to degrade cAMP, causing its local accumulation.
The antiphosphodiesterase activity is concentration depen-
dent, inhibiting the enzyme up to 5% at concentrations of
1×10
−4 M and up to 80% at concentrations of 1×10
−2 M
[29]. In addition, it is time dependent, generating a greater
accumulation of cAMP the longer the incubation time [28].
The accumulation of cAMP generates an increase in
the phosphorylation of the kinase enzyme of the myosin
light chain (MLC) in the cell’s contractile apparatus (actin-
myosin).Inthisstate,theenzymeislesssensitivetoCa2+,and
therefore its activity is diminished. As the enzyme is inhib-
ited, the MLC phosphorylation is diminished and the actin-
myosin interaction is inhibited. This results in an increase
of intracellular Ca2+ concentration without contraction32,
which has been described as a loss of “sensitivity” to Ca2+
[28, 57]. As MLC phosphorylation decreases, the activity of
MLC-phosphatase and relaxation predominate.
Up until now, the kinase enzyme of the myosin light
chain in smooth muscle is the enzyme that activates the
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Figure 2: Typical in vitro vascular response curve of caﬀeine
produced in rabbit aortas with three accumulated caﬀeine doses
(corresponding to the plasmatic concentration obtained upon con-
sumptionofone,two,andthreeespressos).Vasodilationinducedby
the administration of caﬀeine without prior contraction is shown.
It is reproduced with the authorization of Revista Colombiana de
Cardiolog´ ıa
MLC through phosphorylation to a speciﬁc domain. The
agonist stimulation increases the intracellular concentration
of Ca2+ in smooth muscle, causing it to bind to calmodulin,
which when bound to Ca2+ activates the kinase enzyme
in the myosin light chain, thereby activating the form that
interacts with actin to cause contraction. However, more
recentstudieshaveshownthatthismechanismisnottheonly
regulator of the myosin-actin interaction [58].
Rembold et al. [36] observed that upon adding 20mM
of caﬀeine to precontracted arteries, there was an increase
in iCa2+ without a signiﬁcant increase in tone, which could
not be explained solely by the increase in phosphorylation
of MLC kinase. They documented that the Ca2+ had a
heterogeneous distribution. They concluded that caﬀeine
increases iCa2+ but in a region distant from the contractile
apparatus, which therefore did not result in a contraction. It
is probable that this eﬀect of caﬀeine is mediated by cAMP,
since cAMP also increases the “non-contractile” Ca2+ [59].
However, the eﬀects of caﬀeine described cannot be
attributedsolelytotheincreaseincAMP.In1990,Ozakietal.
[56] carried out an observation of precontracted arteries, to
whichcaﬀeineorforskolin(whichalsoincreasescAMP)were
added. At similar levels of cAMP in the two preparations,
caﬀeine inhibited contraction of the VSMC to a greater
degree than forskolin.
5.1.3. Other Direct Mechanisms. Caﬀeine also inhibits inos-
itol triphosphate (IP3) compound which stimulates the
secretion of Ca2+ from the sarcoplasmic reticulum and is
indispensable for contraction. This inhibitory eﬀect of the
IP3 pathway by caﬀeine is antagonized by the addition of
ATP [34]. Given that the xanthenes contain an adenine
ring identical to that of ATP, it has been postulated that
they can interact competitively with the ATP binding site
o nt h eI P 3r e c e p t o r[ 60]. In addition, caﬀeine acts directly
on the voltage-dependent Ca2+ channels in the plasmaticInternational Journal of Vascular Medicine 5
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Figure 3: Vasodilation produced by the direct eﬀects of caﬀeine on the VSMC. Caﬀeine inhibits the voltage-dependent Ca2+ channels
and the entrance of calcium to the cytoplasm. In addition, it inhibits the IP3 receptor and increases the “non-contractile Ca2+.D u et o
its antiphosphodiesterase action, there is an accumulation of cAMP, which increases the non-contractile Ca2+, diminishes cytoplasmic Ca2+
(iCa2+),andinhibitsMyosinLightChainKinase(MLCKinase).ThereforeMLCphosphatasepredominatesandthereisvasodilation.Caﬀeine
also directly inhibits MLC Kinase and the actin-myosin interaction.
membrane to inhibit the entrance of Ca2+ [37], an eﬀect
which is independent of its antiphosphodiesterase action
[38].
Ozaki et al. [35] also demonstrated that caﬀeine acted
directly on the MLC kinase and on the actin and myosin
interaction, slightly inhibiting MLC phosphorylation and
contraction. The direct mechanisms of vasodilation are
illustrated in Figure 3.
More recently, Sandow et al. [61] stated that the modu-
lation of vascular cellular calcium (control of vascular tone,
ﬂow,andbloodpressure)isregulatedbyspecializedsignaling
microdominions in vascular smooth muscle cells, spatially
l o c a t e di nC a 2+ channels and receptors, and interacting
functionally; some studies suggest that these sites are also
present in endothelial cells.
5.2. Indirect Eﬀects. The indirect eﬀects of caﬀeine on the
VSMC occur through NO, synthesized by the eNOS in the
endothelial cell, which diﬀuses rapidly to the VSMC. These
eﬀects are illustrated in Figure 4.
As NO enters the VSMC, it binds to the heme group
of the guanylate cyclase enzyme, activating it. This catalyzes
the conversion of GTP to cGMP, which increases the
activity of a series of cGMP-dependent protein kinases
(PKCs), particularly the Iα type [62]. The PKIα stimulates
the dephosphorylation of the MLC through phosphatase,
producing vasodilation. The PKCs and cGMP also diminish
cytoplasmic Ca2+ and inhibit IP3 [30]. Caﬀeine, in turn,
competitively inhibits 3 5  cGMP phosphodiesterase [20],
stimulating even more accumulation of cGMP.
6.Other Mechanisms ofAction
6.1. Action through Adenosine Receptors. There are diﬀerent
types of adenosine receptors labelled A1, A2a, A2b, and A3.
iCa2+
No Vasodilation
Endothelial cell
Caﬀeine
Oxide nitrosintase
Ca2+
RS
Ca-calmodulin
Figure 4: Indirect eﬀects of caﬀeine on VSMC. Caﬀeine acts on
the endothelial cell increasing cytoplasmic Ca
2+ which will form
the calcium-calmodulin complex which activates the nitric oxide
synthaseenzymetoproducenitricoxide.ThisdiﬀusestotheVSMC.
Caﬀeine acts as a competitive inhibitor of the A1, A2a, and b
receptors [63]. Caﬀeine competitively blocks these receptors
as demonstrated in the experiment carried out by Sattin
and Rall in 1970 [39], but this eﬀect was reversed if more
ATP (adenosine precursor) was added to the preparation.
Paraxanthine, which is the main metabolite of caﬀeine, is an
even more powerful blocker of these receptors than caﬀeine
[2].
The action of adenosine depends on the type of receptor
it stimulates and the type of tissue or cellin whichit is found.
The direct eﬀects of adenosine on the diﬀerent vascular
systems are summarized in Table 2. The local vascular eﬀects
of adenosine are primarily vasodilation of the diﬀerent beds.
This eﬀect depends mainly on the A2a receptors which are
found in high concentrations in vascular tissue [57].
Caﬀeine, by competitively blocking the adenosine recep-
tors, increases its plasmatic concentration [64]w h i c h
increases its systemic eﬀe c t s .A tas y s t e m i cl e v e l ,a d e n o s i n e6 International Journal of Vascular Medicine
Table 2: Vascular eﬀects of adenosine.
Vasculature Eﬀect Receptor
Coronary Vasodilation A2a
Pulmonary
1. Pulmonary artery Vasoconstriction A1
Vasodilation A2a
2. Microcirculation Vasodilation A2b
Mesenteric Vasodilation Unknown
Renal
1. General circulation Vasodilation A2a
2. Aﬀerent arteriole Vasoconstriction A1
Aorta Vasodilation A2b
stimulatesthechemoreceptordistributedthroughoutthecir-
culation, causing a generalized increase in sympathetic tone,
with an increase in circulating catecholamines, peripheral
vascular resistance, and renin secretion [44, 65]. Several
studies have documented an increase in systolic arterial
pressure of 6 to 7.5mmHg and 2.6 to 4mmHg in diastolic
pressure 60 minutes after the administration of 300mg of
caﬀeine (equivalent to drinking a triple espresso) [18, 43].
In spite of this “indirect” vasoconstrictor eﬀect pro-
duced by caﬀeine, it is important to point out that the
chronic consumption of caﬀeine creates a tolerance to
its adenosine receptor-dependent eﬀects. Chronic blocking
of the adenosine receptors, inducing “upregulation”( a n
increase in the number and sensitivity) of the receptors has
been described with a low-moderate caﬀeine consumption
(approximately two cups of coﬀee for more than 5 days)
[66]. A meta-analysis carried out in 1999 [67]d e s c r i b e d
an increase in the systolic and diastolic arterial pressure (2.4
and 1.2mmHg, resp.) with the chronic consumption of 5
cupsofcoﬀeeada y ,ona v erage,whichisac onsiderablylo wer
value from that obtained in studies carried out on subjects
who are not caﬀeine consumers.
This “up-regulation” generates the “abstinence syn-
drome” described by Griﬃths in 1988 [68], characterized by
headache, fatigue, ﬂushing, and anxiety. When you abruptly
stop the consumption of caﬀeine in a habitual consumer,
there is a greater number of available adenosine receptors,
which potentiates the vasodilation produced by adenosine,
causing the symptoms [59, 69, 70].
It has been asserted that the predominant cardiovascular
eﬀects of caﬀeine occur at the adenosine receptors because
much lower concentrations are required (μm) than those
used in studies that show their eﬀect on Ca2+ and phos-
phodiesterase (mM), which are concentrations that are not
attained in vivo [71]. However, in our in vitro studies which
were carried out with micromolar (μm) concentrations of
caﬀeine there was a signiﬁcant vasodilator eﬀect (approxi-
mately 75%) at human consumption concentrations [46].
In vitro studies do not evaluate the systemic response to
caﬀeine, and therefore it is not clear yet which one of the
mechanisms of action predominates in vivo, given that there
are various factors that aﬀect its metabolism and its eﬀects.
6.1.1. Caﬀeine in Relation to Migraine Type Headaches.
Migraines are irregular and episodic which is why there
is no speciﬁc explanation for why a migraine occurs at
any given time. In general it is supposed that exposure
to certain environmental factors combined with individual
internal factors causes migraine episodes. There are reports
that certain dietary, physical, hormonal, emotional, and
environmental factors trigger or cause migraine episodes.
Those most frequently reported include stress, alcohol,
foods, excess or lack of sleep, and weather conditions.
Headaches (migraine) may be related to caﬀeine con-
sumption due to its removal from the usual diet, causing
an abstinence syndrome: an alteration in the normal func-
tioning of the nervous system. The mechanism by which
this occurs is a blocking of the adenosine receptors; when
there is an excessive release of adenosine there is a response
in which the release of neurotransmitter molecules, such
as serotonin, noradrenaline, acetylcholine, and dopamine,
is inhibited, causing an imbalance that can be seen in the
symptoms associated with migraines [72]
Thereisnoclearconclusionthatmigrainescanbecaused
by caﬀeine. Adenosine has opposite eﬀects depending on its
site of action; centrally, in the brain and spinal cord, adeno-
sine acts as an analgesic, but peripherally it can cause pain.
Adenosine dilates blood vessels in the head and neck. The
concentration of adenosine in the head and neck increases
approximately 68% above normal concentrations during
migraine episodes, causing vasodilation and pain [73].
The nervous system compensates the interference of
caﬀeine by releasing more adenosine, increasing the number
of adenosine receptors in the neuron surface, increasing the
aﬃnity of these receptors and decreasing the rate at which
adenosine molecules are removed. All these changes tend to
increasetheactivationofadenosinereceptors,tocompensate
the receptors occupied by caﬀeine.
Caﬀeine is also a common ingredient in many medica-
tionsusedfortreatingmigraines,duetothefactthatitmakes
analgesics work more eﬃciently, causes a faster absorption,
andallowsforareduceddosagewhichdecreasespossibleside
eﬀects of certain analgesics.
6.2. Action through the Activation of the Autonomic Ner-
vous System. Caﬀeine, as it blocks the adenosine receptors,
stimulates a reﬂex activation of the sympathetic system
in conscious patients. Corti et al. [43] demonstrated that
in habitual coﬀee consumers the sympathetic system is
activated,butthisdoesnotleadtoasigniﬁcantincreaseinthe
peripheralvascularresistance,whileinnonconsumers,coﬀee
stimulated the sympathetic system and increased arterial
pressure. In this study it was shown that the consumption
of coﬀee produced an increase in sympathetic tone after
ingesting regular and decaf coﬀee. Although several studies
attribute the increase in arterial pressure to caﬀeine [61,
74], it is possible that there are other substances present
in coﬀee involved in the increase in sympathetic tone and
arterial pressure. In addition, it is important to diﬀerentiate
that the results of diﬀerent studies regarding the eﬀect of
caﬀeineonarterialpressureshowavariationaccordingtothe
population group (hypertensives, stress factors, and age) andInternational Journal of Vascular Medicine 7
also of the design and purpose of each one of these studies.
According to this analysis, the most accurate conclusion is
that tolerance developed with the regular consumption of
caﬀeine diminishes the eﬀect of the same on arterial pressure
approximately 30 minutes after ingestion, with an increase
peak in the range of 1 to 2 hours and a persistence of
approximately 4 hours [75].
Studies have shown that caﬀeine increases plasmatic
levels of stress hormones, including catecholamines such as
adrenaline and noradrenaline and cortisol. These humoral
eﬀects indicate that both the sympathetic-adrenal medullary
system as well as the adrenocorticoid components of the
neuroendocrine response to stress are activated [76, 77].
The ingestion of caﬀeine suggests an increase in sympa-
theticnervousactivityaswellasaslightchangeinphysiologic
v a r i a b l e ss u c ha sb o d yt e m p e r a t u r e ,b l o o dp r e s s u r e ,a n d
heart rate. It has been shown that many pharmacologic
eﬀects of caﬀeine are related to the sympathetic nervous
system. Certain doses, especially high ones, may cause
tachycardia, a signiﬁcant increase in plasmatic adrenaline
concentrations, an increase in the plasmatic activity of renin,
as well as thermogenic and lipolytic eﬀects. This eﬀect on
sympathetic activity presents variable results and continues
to be controversial and only partially understood [78]
6.3. Action through the Renin-Angiotensin-Aldosterone Axis
(RAA). Caﬀeine has three main eﬀectson the RAA axis [41].
First of all, it blocks the inhibiting eﬀect of adenosine on the
juxtaglomerular cells in the kidney, increasing the secretion
of renin [79]. In addition, due to its antiphosphodiesterase
activity, it increases the concentration of cAMP, which is a
precursor of rennin, and also increases the secretion of renin
by activating the sympathetic system [42]. Theoretically, this
increase in renin secretion results in vasoconstriction and an
increase in peripheral vascular resistance.
Caﬀeine only has this eﬀect in conditions in which renin
is elevated (e.g., cirrosis, congestive heart failure) and not in
normal physiologic conditions. For this reason, in healthy
people,caﬀeinedoesnotsigniﬁcantlyaﬀectreninproduction
[80, 81].
7. Conclusions
Coﬀee is one of the most consumed beverages worldwide
and is the primary export of Colombia. It has a composition
of over 2,000 substances, with a predominance of carbo-
hydrates, lipids, amino acids, melanoidins, and the most
important and well-known of all caﬀeine. In this paper some
of the currently known vascular mechanisms of action of
caﬀeine are described.
Caﬀeine is a xanthine which displays several mechanisms
of action on the vascular wall, especially on the endothelial
tissue and the vascular smooth muscle cell VSMC. At the
same time, it is known that it acts on the autonomic nervous
system and on arterial pressure, with a possible development
of tolerance with regular consumption.
The eﬀects it produces are the result of the activation
or blocking of diﬀerent types of receptors, such as those
of adenosine, IP3, NO, among others. In addition, its
eﬀects seem to be contradictory depending on the cellular
structure and the time of exposure over which it acts. A mild
and transitory vasoconstrictor eﬀect exists, which depends
mainlyonthe caﬀeineconcentrationinthe VSMC.However,
the main and predominant eﬀect of caﬀeine on the vascular
wall is vasodilating, acting equally on the VSMC directly
or indirectly and also on the endothelial structure. At the
endothelial level, nitric oxide is liberated and as a result
produces arterial vasodilation. It has been shown that this
eﬀect is caused in the presence or absence of preserved
endothelial function.
As for the eﬀects on the vascular smooth muscle cell,
caﬀeine causes direct and indirect eﬀects according to the
type of stimulus, either at the level of cellular Ca2+ con-
centrations or on competitive eﬀects with speciﬁc enzymes.
Indirectly, the diﬀusion of nitric oxide from the endothelial
tissue towards the VSMC increases the vasodilator eﬀect.
In spite of being a widely consumed substance world-
wide, its vascular eﬀect, and cardiovascular eﬀect in general,
continues to be controversial. It is evident that the eﬀects of
coﬀeeconsumptionvarynotablyaccordingtothepopulation
being studied and speciﬁc metabolic and pathologic factors.
For this reason, it is necessary to continue the search for
greater information regarding the eﬀects and mechanisms
of action of caﬀeine, in order to determine the impact of
the mechanisms as risk factors or if said mechanisms can be
considered protective at a cardiovascular level.
Abbreviations and Acronyms
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